ESH MDS 2021 | Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246
Revised International Prognostic Scoring System (IPSS-R) higher-risk myelodysplastic syndrome (MDS) refractory and relapsed (R/R) to hypomethylating agents (HMAs), such as azacitidine and decitabine represents an unmet medical need, with few treatment options available. Valeria Santini, MD, University of Florence, Florence, Italy, discusses some options for this patient group, like the addition of venetoclax and other active agents to the HMA treatment backbone. Prof. Santini discusses pevonedistat, a first in class NEDD8-activating enzyme (NAE) inhibitor, sabatolimab, a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3 and APR-246 an investigational small molecule targeting the tumor suppressor protein, p53. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
